Sign in

    Solventum (SOLV)

    Q2 2024 Earnings Summary

    Reported on Jan 10, 2025 (After Market Close)
    Pre-Earnings Price$58.66Last close (Aug 8, 2024)
    Post-Earnings Price$60.00Open (Aug 9, 2024)
    Price Change
    $1.34(+2.28%)

    What went well

    • Solventum is accelerating talent acquisition ahead of schedule, bringing in experienced leaders to drive rigorous commercial execution, which is expected to contribute to growth starting in the back half of 2024 and into 2025.
    • The company is confident in its business continuity efforts post-separation from 3M, leading to raised top and bottom-line guidance for 2024.
    • Solventum is implementing the "Solventum Way" restructuring project to streamline its structure, enhance autonomy, speed, and accountability, aiming to drive revenue growth and margin expansion over time.

    What went wrong

    • The company expects significant cost pressures in 2025 due to the annualization of post-spin expenses, including increased supply costs from the 3M supply agreement markup, higher functional expenses to stand up new functions, and elevated interest expense. This is anticipated to pressure operating margins and earnings per share in 2025.
    • Management acknowledges that 2025 will be a tough year for earnings per share (EPS), with expected declines, and does not anticipate EPS growth until 2026.
    • The turnaround plan is expected to take several years to yield results, with meaningful revenue acceleration not expected until 2026 or beyond, indicating that the company's growth may lag in the near term.

    Q&A Summary

    1. Guidance Raise Drivers
      Q: What's driving the raised guidance?
      A: The guidance increase is driven by three factors: strong business continuity, backorder recovery banked in Q2, and better clarity on SKU rationalization impacts shifting to 2025.

    2. EPS Growth Outlook
      Q: When will earnings start growing again?
      A: 2025 will be a tough year for EPS due to annualization of post-spin costs, but we expect earnings to begin recovering in 2026.

    3. Restructuring Plans
      Q: Are you starting cost rationalization now?
      A: Yes, we're streamlining our structure to drive a culture shift towards speed and accountability, which will lead to growth and margin expansion.

    4. Strategic Turnaround Timing
      Q: Update on the 5-year turnaround outlook?
      A: We're focusing on faster-growth markets, shifting resources, and implementing four growth accelerators. Talent upgrades will impact late '24 into '25; R&D productivity will affect 2026 and beyond.

    5. Segment Revenue Drivers
      Q: Which segments drive revenue guidance raise?
      A: Strength is seen across the board, notably from backorder recovery in MedSurg, but we don't break down guidance by segment.

    6. Operating Margins Outlook
      Q: Outlook for operating margins and cash flow?
      A: Despite headwinds, we're confident in 21%-23% operating margin for the year. Increased cash use in H2 due to intercompany settlements and ramping capital expenditures.

    7. Corporate Revenue Allocations
      Q: Should we include $22M corporate revenues forward?
      A: Yes, the approximate $22 million in corporate and allocated revenues is expected per quarter for the rest of the year.

    8. Tax Rate Expectations
      Q: Is 20%-21% tax rate in H2 fair?
      A: Yes, after a favorable first half, the second half tax rate is expected to be similar to our full-year expectations.

    9. Activist Investor Discussions
      Q: Feedback on conversations with the activist?
      A: We don't discuss individual investors, but we listen to shareholder feedback and appreciate it.

    10. FX Assumptions
      Q: Any update on FX assumptions?
      A: No change; we expect a 50 basis points impact on revenue from FX for the full year.

    Analyst Coverage

    Research analysts covering Solventum.

    Related Publications